Arvinas, Inc - ARVN STOCK NEWS

Arvinas, Inc. (Nasdaq: ARVN) announced a board transition on August 18, 2022, with Liam Ratcliffe stepping down and John Young joining the Board of Directors. Ratcliffe, a significant contributor since 2015, was thanked by CEO John Houston for his guidance. Young, with nearly 35 years at Pfizer and experience in senior roles, is expected to contribute valuable insights as Arvinas approaches late-stage development. The company is dedicated to creating therapies targeting disease-causing proteins, with ongoing clinical programs for prostate and breast cancer treatments.

Arvinas, Inc. (Nasdaq: ARVN) announced the appointment of Lisa Sinclair as Senior Vice President of Corporate Operations. With over 25 years in the biopharmaceutical industry, Sinclair previously held key roles at Rallybio and AstraZeneca. Arvinas CEO John Houston emphasized her strategic operational experience as crucial for the company's planned entry into pivotal clinical trials by year-end. Arvinas is focused on developing therapies that degrade disease-causing proteins using its proprietary PROTAC® platform, aiming to enhance the lives of patients with serious diseases.

Arvinas, Inc. (Nasdaq: ARVN) reported its Q2 2022 financial results, highlighting revenues of $31.3 million, a significant increase from $5.5 million in Q2 2021. The net loss rose to $70.0 million from $50.3 million, attributed to higher R&D and administrative costs. The company plans to initiate pivotal trials for ARV-471 and bavdegalutamide in metastatic cancers, with the Phase 3 trial set for 2H 2023. As of June 30, 2022, cash and equivalents were $1,347.7 million, sufficient to fund operations beyond 2024.

Arvinas, Inc. (Nasdaq: ARVN) has appointed John Northcott as the Chief Commercial Officer (CCO), a new role in the company. Northcott brings extensive experience from notable companies like Nektar Therapeutics and Pharmacyclics, where he successfully led product development and commercialization. CEO John Houston expressed confidence that Northcott's expertise will significantly aid in advancing Arvinas' drug pipeline, especially as the company prepares for late-stage development. Arvinas specializes in therapies that target and degrade disease-causing proteins, aiming to improve outcomes in cancer treatments.

Arvinas, a clinical-stage biotechnology firm listed on Nasdaq under the symbol ARVN, announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference scheduled for June 13 at 4:20 p.m. ET. The event will feature a fireside chat with the company's management in Rancho Palos Verdes, California. A live audio webcast will be available on the company's website. Arvinas focuses on developing therapies that degrade disease-causing proteins, utilizing its proprietary PROTAC® technology, with ongoing clinical programs targeting prostate and breast cancer.

Arvinas, a clinical-stage biotechnology company, announced a $25,000 Early Career Research Award to honor 20 years of targeted protein degradation. This award aims to recognize innovative research efforts in the field, with nominations open until August 1, 2022. The winner will be presented at the 5th Annual Targeted Protein Degradation Summit in October 2022. Arvinas emphasizes its commitment to advancing biotechnology through innovative therapies that degrade disease-causing proteins.

GNS Healthcare announced a collaboration with Arvinas (ARVN) aimed at accelerating drug development for neurodegenerative diseases. By utilizing GNS' Gemini Virtual Patient models, Arvinas seeks to gain insights into disease progression, enhancing drug candidate selection and clinical trial efficiency. With over six million new diagnoses of Alzheimer's, Parkinson's, and Huntington's diseases annually in the U.S., this partnership intends to improve patient outcomes through targeted protein degradation therapies. Both companies emphasize a commitment to advancing treatment options for these chronic conditions.

Arvinas, Inc. (Nasdaq: ARVN) reported its Q1 2022 financial results, highlighting a productive quarter with plans for three pivotal clinical trials in 2022. Revenue surged to $24.2 million, up from $5.5 million in Q1 2021, driven by collaborations, particularly the ARV-471 program. However, net loss increased to $63.4 million from $41.0 million, primarily due to rising R&D and administrative costs. Cash reserves decreased to $1.43 billion. Key milestones include ongoing trials for ARV-471 and bavdegalutamide while preparing for potential FDA discussions.

Arvinas, a clinical-stage biotechnology company, announced participation in the Bank of America Securities 2022 Healthcare Conference on May 10 at 7:00 p.m. ET in Las Vegas. The event will feature a fireside chat with management, and a live audio webcast will be available on the company's website. Arvinas specializes in targeted protein degradation therapies, utilizing its proprietary PROTAC® Discovery Engine platform. The company has three clinical-stage programs focused on various cancers, including prostate and breast cancer.